Fig. 6

The JAK2 inhibitor AZD1480 reversed the paradoxical proliferation caused by FGF2. A. Spheroid images show the effects of the JAK1 inhibitor Solcitinib (1.0 µM) and the JAK2 inhibitor AZD1480 (0.2 µM) on FGFR1 amplified cells (CAMA1 and MDA-MB-134) and non-amplified cells (MCF7 and T47D) with and without FGF2 treatment (25 ng/mL) for 14 days. Bar equals 1000 μm. B. Relative fold change of ratio between cell number in + FGF2 vs. -FGF2 spheroids is calculated for each treatment. The ratios in DMSO treatment are used as controls and are set to a fold of one. C. Immunoblotting shows the effect of specific FGFR inhibitors (1.0 µM for all FGFR inhibitors) on p21 expression levels, JAK2 and Stat1/3 activation in ER + cell 3D cultures after 72 h of treatment with FGF2 (25 ng/mL)